Some cancer cells go into a dormant state, akin to seeds lying latent in soil, remaining inactive within the body for extended periods. These “sleeper cells” spread throughout the body can remain quiet for years. However, when the body encounters a respiratory virus like influenza or SARS-CoV-2, the resulting inflammation serves as a wake-up call for these silent cells, particularly in the lungs, providing an opportunity for them to grow and spread.
A recent study published in Nature has shed light on how viral infections can transform dormant cancer cells into an active and lethal threat, elevating the chances of metastasis and cancer-related mortality. Researchers from the University of Colorado Cancer Center conducted experiments in mice, demonstrating that viral infections can revive dormant breast cancer cells, leading to rapid multiplication and the formation of metastatic strongholds in the lungs within a short span.
During the COVID-19 pandemic, a critical question emerged: could respiratory viruses like the flu or SARS-CoV-2 play a role in the resurgence of cancer? Mice engineered with dormant breast cancer cells in their lungs showed a remarkable response when infected with either flu or SARS-CoV-2, with the previously dormant cancer cells rapidly multiplying over a hundredfold. The lungs quickly turned into battlegrounds of aggressive tumor growth, underlining the alarming potential of viral inflammation to trigger metastatic reactivation.
The implications of this research extend beyond breast cancer, suggesting that viral inflammation may serve as a universal trigger for awakening dormant cancer cells, with broader implications for cancer metastasis. Data analysis from the UK and the US revealed that individuals with a history of cancer who contracted COVID-19 faced a heightened risk of cancer-related mortality, particularly within a year of infection. This increased risk aligns with the findings from the mouse experiments, where viral infections spurred rapid growth of dormant cancer cells.
Interleukin-6 (IL6) emerges as a key player in this process, acting as a biochemical alarm signal during inflammation and facilitating the transition of cancer cells from dormancy to aggressive growth. Blocking IL6 with specific antibodies in severe COVID cases could potentially mitigate the body’s exaggerated immune response and improve survival rates. The study also hints at existing FDA-approved drugs that target these biological pathways, potentially reducing the risk of cancer spread in survivors of viral lung infections like COVID-19 or the flu.
Future research aims to delve deeper into the mechanisms through which viral infections reawaken dormant cancer cells, exploring strategies to block this process and harness the immune system to eliminate reactivated cells. Critical questions regarding the influence of cancer type on post-infection risks, the potential sites of metastasis beyond the lungs, and the impact of vaccination against respiratory viruses on reducing these risks will be addressed in forthcoming studies. These investigations could pave the way for novel approaches to safeguard cancer survivors from metastatic resurgence triggered by viral illnesses.
Key Takeaways:
– Viral infections like COVID-19 can awaken dormant cancer cells, increasing the risk of metastasis and cancer-related mortality.
– Interleukin-6 (IL6) plays a pivotal role in transitioning cancer cells from dormancy to aggressive growth during inflammation.
– Existing FDA-approved drugs targeting IL6 pathways may hold promise in reducing the risk of cancer spread in survivors of viral lung infections.
– Future research aims to uncover the biological mechanisms behind viral reactivation of dormant cancer cells and explore strategies to prevent metastatic resurgence post-viral illness.
Read more on newatlas.com